Sentence examples for the human panel from inspiring English sources
The human panel study showed that Participant Reported Outcomes (PROs) for the perceived stickiness in the mouth and disintegration time of test films received significantly different scores between samples, and thus were identified as the key attributes with the potential to affect the end-user acceptability.
The human panel of 157 miRNAs screened in the study included three other miRNAs located in this region, miR-134, miR-337, and miR-342, but their expression did not have any statistical significance associated with APML samples.
A total of 229 polymorphic sites in African-Americans and 125 polymorphic sites in European-Americans were found in the human panel, eight of which resulted in amino acid changes.
The human panel early access kit (P/N: 4365381, Applied Biosystems) used in this study contained 160 individual assays and comprised two steps: Reverse Transcription (RT) and real time PCR.
The human panel of cytokines/chemokines that was assayed in this study was composed of the following interleukins (IL): IL-1 β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, and IL12; tumor necrosis factor-alpha (TNF- α); vascular endothelial growth factor (VEGF); granulocyte-macrophage-colony stimulating factor (GM-CSF); and interferon-gamma (IF- γ).
In the whole human panel, the first exon showed significantly negative Fu and Li's F and F* values (P<0.05, table 1).
In separate reactions, random hexamers (Applied Biosystems) at a concentration of 10 μM were employed for 18S reverse transcription, whereas miRNA-specific stem-loop primers available in the Applied Biosystems Taqman® MicroRNA Assays, Human Panel Early Access kit were used for target-specific miRNA reverse transcription according to the manufacturer's instructions.
Three of the newly synthesized compounds were tested for anticancer activity in the National Cancer Institute (NCI) against human panel breast cancer cell line MCF7, from the in vitro assays compound 6c presented promising anti-cancer activity using Doxorubicin as a reference.
Total RNAs were reverse transcribed and TaqMan PCR reactions were carried out using the TaqMan MicroRNA Assays Human Panel Early Access Kit (Life Technologies-Applied Biosystems, Foster City, CA, USA).
The human RNA panel was purchased from Clontech (Human Total RNA master Panel II).
Building upon the productive body of work on mobile source PM in the first 6 years of PM Center work, the current PM Centers include human panel and clinical studies and toxicologic studies in laboratory animals and in vitro systems that test hypotheses about the effects of mobile source PM exposures.
